Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's NexSys PCS adoption and hospital recovery signal growth ahead, but a leveraged balance sheet and stiff competition still cloud the stock's outlook.
Here's Why Haemonetics (HAE) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Haemonetics (HAE) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics Q3 Earnings & Revenues Beat, Margins Up, Stock Slips
HAE beats Q3 EPS and revenue estimates as margins expand sharply, but sales fall 2.7% year over year, sending shares down after the report.
Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026
Intellia Therapeutics is reinstated as a Buy, driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Phase 3 lonvo-z HAE data readout, both with significant valuation impact. Lonvo-z offers potential for a one-time, functional cure in HAE, with strong efficacy and a manageable safety profile, but market adoption hinges on Phase 3 results.
Haemonetics (HAE) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.19 per share a year ago.
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Haemonetics' plasma and hemostasis franchises show solid growth potential, but macro headwinds and competition cloud the near-term outlook.
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
